Profile data is unavailable for this security.
About the company
Collegium Pharmaceutical, Inc. is a diversified biopharmaceutical company. The Company has developed, licensed, and acquired a portfolio of products for use in the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. Its commercial products include Jornay PM (Jornay), Belbuca, Xtampza ER (Xtampza), Nucynta ER and Nucynta IR (Nucynta Products), and Symproic in the United States. Its Jornay is a central nervous system (CNS) stimulant prescription medicine for the treatment of ADHD. The Belbuca is a buccal film that contains buprenorphine for severe and persistent pain. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone. The Xtampza ER is a pain treatment option designed with abuse deterrent properties. The Nucynta Products are ER and IR oral formulations of tapentadol. Nucynta ER is indicated for the management of severe and persistent pain that requires an extended treatment period with a daily opioid analgesic.
- Revenue in USD (TTM)780.57m
- Net income in USD62.87m
- Incorporated2014
- Employees423.00
- LocationCollegium Pharmaceutical Inc100 Technology Center DrSTOUGHTON 02072-4710United StatesUSA
- Phone+1 (781) 713-3699
- Websitehttps://www.collegiumpharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Phathom Pharmaceuticals Inc | 175.11m | -221.25m | 903.03m | 371.00 | -- | -- | -- | 5.16 | -3.05 | -3.05 | 2.40 | -6.14 | 0.5494 | 5.18 | 3.00 | 471,994.60 | -69.41 | -77.19 | -105.43 | -94.72 | 87.09 | -- | -126.35 | -475.57 | 1.69 | -2.47 | 3.95 | -- | 216.93 | -- | 33.82 | -- | -26.11 | -- |
| Amphastar Pharmaceuticals Inc | 719.89m | 98.09m | 953.23m | 1.98k | 10.33 | 1.22 | 6.16 | 1.32 | 2.03 | 2.03 | 14.93 | 17.28 | 0.449 | 2.20 | 5.14 | 364,315.30 | 6.12 | 9.83 | 6.82 | 11.35 | 49.46 | 50.52 | 13.63 | 18.26 | 2.90 | 8.36 | 0.4362 | 0.00 | -1.65 | 15.53 | -38.51 | 133.84 | 1.87 | -- |
| Theravance Biopharma Inc | 80.33m | 29.34m | 960.24m | 97.00 | 33.68 | 4.13 | 30.98 | 11.95 | 0.5626 | 0.5626 | 1.59 | 4.59 | 0.2082 | -- | 4.58 | 828,113.40 | 7.61 | -34.51 | 8.26 | -40.08 | -- | -- | 36.53 | -254.51 | -- | -- | 0.1216 | -- | 12.12 | -2.59 | -2.22 | -- | -36.34 | -- |
| Xeris Biopharma Holdings Inc | 266.14m | -15.64m | 998.86m | 394.00 | -- | -- | -- | 3.75 | -0.1033 | -0.1033 | 1.67 | -0.0052 | 0.77 | 0.7301 | 5.61 | 675,474.60 | -4.52 | -31.61 | -6.46 | -42.28 | 84.56 | 79.76 | -5.88 | -77.77 | 1.35 | 0.3853 | 1.00 | -- | 23.89 | 136.89 | 11.92 | -- | -4.75 | -- |
| Day One Biopharmaceuticals Inc | 158.18m | -107.32m | 1.07bn | 178.00 | -- | 2.42 | -- | 6.77 | -1.04 | -1.04 | 1.53 | 4.28 | 0.2901 | 3.57 | 7.79 | 888,662.90 | -19.68 | -32.37 | -22.44 | -35.43 | 89.12 | -- | -67.85 | -209.67 | 7.91 | -- | 0.00 | -- | 20.60 | -- | -12.38 | -- | 110.70 | -- |
| Precigen Inc | 6.31m | -425.87m | 1.28bn | 143.00 | -- | 30.59 | -- | 203.02 | -1.40 | -1.40 | 0.0212 | 0.1183 | 0.0495 | -- | 11.92 | 44,118.88 | -193.82 | -38.49 | -245.09 | -47.33 | 30.32 | 49.53 | -3,912.92 | -334.29 | 3.95 | -- | 0.6893 | -- | -36.95 | -46.64 | -31.63 | -- | -25.69 | -- |
| Collegium Pharmaceutical Inc | 780.57m | 62.87m | 1.32bn | 423.00 | 24.32 | 4.37 | 4.57 | 1.69 | 1.71 | 1.71 | 20.54 | 9.51 | 0.4702 | 8.30 | 3.55 | 1,845,312.00 | 3.79 | 3.89 | 5.30 | 5.96 | 59.35 | 56.32 | 8.05 | 8.34 | 1.48 | 2.65 | 0.7285 | 0.00 | 23.62 | 20.28 | -9.13 | 18.64 | -65.83 | -- |
| EyePoint Inc | 42.34m | -205.75m | 1.52bn | 165.00 | -- | 6.37 | -- | 35.86 | -2.99 | -2.99 | 0.617 | 2.88 | 0.1532 | 1.02 | 59.51 | 256,606.10 | -74.47 | -35.88 | -86.87 | -42.05 | 94.08 | 84.82 | -485.95 | -201.78 | 7.11 | -- | 0.00 | -- | -5.97 | 16.27 | -84.86 | -- | 80.24 | -- |
| Immunocore Holdings PLC - ADR | 400.02m | -35.51m | 1.66bn | 524.00 | -- | 4.35 | -- | 4.14 | -0.7057 | -0.7057 | 7.87 | 7.52 | 0.3852 | 0.8348 | 5.84 | 763,389.30 | -3.42 | -11.69 | -4.39 | -14.93 | 98.73 | -- | -8.88 | -32.06 | 4.01 | -- | 0.5078 | -- | 28.95 | 59.62 | 30.48 | -- | 1.95 | -- |
| Harmony Biosciences Holdings Inc | 868.45m | 158.69m | 1.67bn | 293.00 | 10.65 | 1.92 | 9.08 | 1.92 | 2.71 | 2.71 | 14.87 | 15.07 | 0.7649 | 31.60 | 9.66 | 2,964,004.00 | 13.98 | 17.23 | 17.21 | 20.92 | 77.16 | 78.84 | 18.27 | 22.32 | 3.58 | -- | 0.1583 | -- | 21.51 | 40.30 | 9.07 | -- | 528.16 | -- |
| ANI Pharmaceuticals Inc | 826.88m | 34.14m | 1.69bn | 897.00 | 46.13 | 3.34 | 12.93 | 2.04 | 1.63 | 1.63 | 40.89 | 22.51 | 0.6135 | 2.18 | 3.68 | 921,828.30 | 3.01 | -2.99 | 3.63 | -3.49 | 61.14 | 58.84 | 4.91 | -6.12 | 2.04 | 3.83 | 0.5508 | -- | 26.20 | 24.36 | -230.19 | -- | 19.60 | -- |
| Innoviva Inc | 411.33m | 271.17m | 1.69bn | 159.00 | 7.38 | 1.45 | 5.43 | 4.11 | 3.10 | 3.10 | 5.18 | 15.71 | 0.2802 | 2.84 | 4.58 | 2,586,969.00 | 18.47 | 17.66 | 20.46 | 19.58 | 74.80 | -- | 65.92 | 58.96 | 13.85 | -- | 0.1802 | -- | 14.67 | 4.08 | 1,059.22 | 3.86 | 281.45 | -- |
| Perrigo Company PLC | 4.25bn | -1.40bn | 1.70bn | 8.10k | -- | 0.5784 | -- | 0.3994 | -10.19 | -10.36 | 30.80 | 21.33 | 0.4678 | 2.47 | 6.37 | 525,074.10 | -15.42 | -3.52 | -17.39 | -4.03 | 35.14 | 34.70 | -32.97 | -8.36 | 1.63 | 1.91 | 0.5536 | -- | -2.75 | 0.794 | -772.62 | -- | -14.60 | 5.21 |
| Sarepta Therapeutics Inc | 2.20bn | -842.79m | 1.71bn | 1.37k | -- | 1.50 | -- | 0.7793 | -8.44 | -8.44 | 21.50 | 10.87 | 0.6012 | 1.01 | 4.40 | -- | -23.05 | -12.81 | -30.73 | -15.87 | 61.81 | 77.84 | -38.34 | -30.61 | 1.48 | -853.14 | 0.4209 | -- | 15.58 | 32.41 | -403.27 | -- | -- | -- |
| Veradermics Inc | 0.00 | -53.81m | 1.74bn | 19.00 | -- | -- | -- | -- | -1.53 | -1.53 | 0.00 | 0.3731 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -60.63 | -- | -- | -- |
Data as of Mar 03 2026. Currency figures normalised to Collegium Pharmaceutical Inc's reporting currency: US Dollar USD
57.35%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 31 Dec 2025 | 4.48m | 14.17% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 1.99m | 6.29% |
| Eventide Asset Management LLCas of 31 Dec 2025 | 1.88m | 5.94% |
| Renaissance Technologies LLCas of 31 Dec 2025 | 1.62m | 5.12% |
| Fuller & Thaler Asset Management, Inc.as of 31 Dec 2025 | 1.50m | 4.75% |
| Rubric Capital Management LPas of 31 Dec 2025 | 1.50m | 4.73% |
| Principal Global Investors LLCas of 31 Dec 2025 | 1.31m | 4.16% |
| Massachusetts Financial Services Co.as of 31 Dec 2025 | 1.31m | 4.15% |
| SSgA Funds Management, Inc.as of 31 Dec 2025 | 1.31m | 4.15% |
| Janus Henderson Investors UK Ltd.as of 31 Dec 2025 | 1.23m | 3.90% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
